header logo image


Page 258«..1020..257258259260..270280..»

Aftereffects of COVID-19 can cloud the brain, or even cause strokes – CT Insider

December 26th, 2020 1:55 pm

NEW HAVEN As the COVID-19 pandemic enters its second year, neurologists are finding that patients frequently suffer difficulties in concentration and memory, even after recovering from the acute illness.

In some cases, chemicals formed to fight the coronavirus are causing bleeding in the brain and even strokes, though the instances of these are rare.

Dr. Serena Spudich, a neurologist with the Yale School of Medicine, is one of a team operating a neuro-COVID clinic, which has been see patients via telehealth visits. The clinic began seeing patients monthly, but now is run four times a month. There have been about 30 patients seen so far, Spudich said.

As the pandemic has progressed, we started to realize that there seemed to be some impact in the nervous system and that was something that other clinicians, other investigators in Asia and Italy and the United Kingdom were seeing, Spudich said.

The neurological issues patients were having after the major COVID symptoms had gone were so frequent that a specialized clinic was created within the Yale Medicine practice, including Dr. Shelli Farhadian and Dr. Lindsay McAlpine.

We wanted to get prepared because we realized there would be a variety of conditions that patients would be coming in with, Spudich said.

Headache has been one of the most common complaints, some of them persistent or severe enough to interfere with daily living, Spudich said. Other issues contribute to brain fog.

The primary concern is the sense that they are having trouble with concentration, memory and daily functioning in their lives, Spudich said.

Patients reported that they could not focus on their work or studies or had difficulty falling asleep or waking up.

Many of these issues are fairly subtle for the patients, so they may be able to function on a daily basis, she said. But the range of neurological symptoms has been broad, including a burning sensation on the skin, weakness and visual changes.

Its not the majority that theyre so debilitated that they cant work, Spudich said. Perhaps a fifth suffer that severely.

For most, its really remarkable what people continue to work through, she said.

Besides physical symptoms, theres also a significant mental health issue that some patients are exhibiting, including depression, anxiety and post-traumatic stress disorder, Spudich said. Theres always been a link thats been presumed between brain inflammation and some mental health and mood disorders.

Dr. Arman Fesharaki-Zadeh, a behavioral neurologist and neuropsychiatrist, is part of the clinics team.

Its not necessarily the coronavirus that causes neurological problems. Often its the bodys attempt to fight off the infection, the doctors noted.

One major issue with COVID is it causes a lot of inflammation in the body, Spudich said. That triggers the bodys immune system, which releases cytokines, proteins such as interferon and interleukin.

While not necessarily a cytokine storm that overwhelms the body, the response still can cause problems when the chemicals pass through inflamed blood vessels into the brain.

It doesnt seem that the virus, SARS-CoV-2, which causes COVID, is robustly affecting the brain, which is good, but even though maybe the virus itself isnt attacking the brain the immune response seems to be causing these problems, Spudich said.

Many of these patients were seeing were never severely ill. They were never severely ill in the ICU, Spudich said, but the cytokines released by immune cells are enough to cause lingering aftereffects.

It may be that addressing immune issues would address all the underlying issues that were seeing, she said. Theres so much we dont know. This is all the best hazard of a guess. What were doing basically is trying to listen to each patients story, how sick were they, what kind of lab values did they have, how long were they sick, what they were treated with.

In some cases, COVID may have exacerbated neurological problems the patient had before; in other cases they could be new symptoms.

While the neuro-COVID clinic treats patients, Dr. Amit Mahajan, assistant professor of radiology and biomedical imaging at Yale School of Medicine, has been researching the effects of the disease on the brain, using CT scans and MRIs. He is corresponding author of a study in the American Journal of Radiology of patients in the New York metropolitan area at the beginning of the pandemic.

What Mahajan and his co-authors found was a number of brain bleeds and clots forming in the brains of COVID patients. The numbers are small. In another study, 8.4 percent of admitted patients had such severe symptoms, he said. The number would be lower if all COVID patients were scanned.

Most of the problems, the real serious problems that happen with COVID, are due to something called inflammation in the blood, Mahajan said. And a lot of the people have developed clots because of the inflammation If they go and occlude the vessels of the brain, they may cause a stroke as well.

Problems also develop when the bodys clotting and anti-clotting processes are out of balance. Then you can not only have clots, you can also have bleeding, Mahajan said. The problem can be made worse if a patient is given blood-thinning medication, he said.

Another issue is what Mahajan called post-infectious phenomena, in which an immune response to the infection can cause its own problems. And that would include things like Guillain-Barre syndrome, in which the immune system attacks the nerves, as well as multisystem inflammatory syndrome in children.

For more information about the neuro-COVID clinic, call 203-785-4085.

edward.stannard@hearstmediact.com

See the rest here:
Aftereffects of COVID-19 can cloud the brain, or even cause strokes - CT Insider

Read More...

Exosome therapeutic Market 2020 Global Industry Growth, Trends, COVID-19 Impact Analysis, Share, Size and 2027 Forecasts Report – Farming Sector

December 26th, 2020 1:54 pm

Exosome therapeutic Market Industry Trends and Forecast to 2027 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.

Exosome therapeutic Market Statistical Overview Report 2020 gives an outstanding tool for market Survey, openings, and Vital key and strategic basic leadership. This report perceives that in this quickly advancing and competitive scenario, up-coming data on the basis of research execution and settle on basic choices for development and benefit. It gives data on Exosome therapeutic Market trends and advancements and sheds light on various sectors, limitations and advancements, and on the evolving structure of the market.

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ [emailprotected]

Read the original post:
Exosome therapeutic Market 2020 Global Industry Growth, Trends, COVID-19 Impact Analysis, Share, Size and 2027 Forecasts Report - Farming Sector

Read More...

Report On Canine Stem Cell Therapy Market to 2026: (Industry Insights, Company Overview and Investment Analysis) – Farming Sector

December 24th, 2020 6:59 am

Canine Stem Cell Therapy Market report shows the Industry Chain Structure as well as Macroeconomic Environment Analysis and Development Trend. The Canine Stem Cell Therapy Market report also provides the market impact and new opportunities created due to the COVID19/CORONA Virus catastrophe. The total market is further divided by company, by country, and by application/types for the competitive landscape analysis. The report then estimates 2020-2026 market development trends of Canine Stem Cell Therapy Industry.

TheCanine Stem Cell Therapy market report gives CAGR value, Industry Chains, Upstream, Geography, End-user, Application, Competitor analysis, SWOT Analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast. The report also gives insight on entry and exit barriers of the industry.

Get Exclusive Sample of Report on Canine Stem Cell Therapy market @ https://www.alltheresearch.com/sample-request/206

The Canine Stem Cell Therapy Market Report Covers Major Players:

Canine Stem Cell Therapy Market Breakdown Data by its type

Canine Stem Cell Therapy Market Breakdown Data by its Application

Canine Stem Cell Therapy Consumption Breakdown Data by Region: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Malaysia, Philippines, Thailand, Vietnam, Europe, Germany, France, UK, Italy, Russia, Rest of Europe, Central & South America, Brazil, Rest of South America, Middle East & Africa, GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa.

The Study Objectives of Canine Stem Cell Therapy Market Report are:

Any Customization required? Request here @ https://www.alltheresearch.com/customization/206

Major Points from Table of Contents:

Ask Your Queries to our Analyst regarding Canine Stem Cell Therapy Report @ https://www.alltheresearch.com/speak-to-analyst/206 Frequently Asked Questions:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan

Email: [emailprotected]

Phone: +1 (407) 768-2028

Follow this link:
Report On Canine Stem Cell Therapy Market to 2026: (Industry Insights, Company Overview and Investment Analysis) - Farming Sector

Read More...

Stem Cell Therapy Market to See Massive Growth by 2026 Osiris Therapeutics, NuVasive – Farming Sector

December 24th, 2020 6:59 am

The latest version of the 2020 market study on Stem Cell Therapy Market comprising 104 with market data Tables, Charts, Graphs, and Figures which are easy to understand with showcased in-depth analysis.

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. This has led to several changes in market conditions. The report covers the rapidly changing market scenario and the initial and future impact assessments.

The global Stem Cell Therapy market was valued at $XX million in 2019, and Research analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2020 and 2029.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies: https://www.amplemarketreports.com/sample-request/2020-2029-global-stem-cell-therapy-market-2022421.html

As per the research and study, the market has settled its presence worldwide. Stem Cell Therapy Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Glancing to 2020, the global market expected to be a significant year for Stem Cell Therapy Market in terms of growth and revenue.

Almost all companies who are listed or profiled are being to upgrade their applications for end-user experience and setting up their permanent base in 2020. This report focused and concentrate on these companies including Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix).

Furthermore, the research contributes an in-depth overview of regional level break-up categorized as likely leading growth rate territory, countries with the highest market share in past and current scenario. Some of the geographical break-up incorporated in the study are North America (United States, Canada and Mexico), Europe (Germany, UK, France, Italy, Russia and Spain etc.), Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.), South America (Brazil, Argentina and Colombia etc.), Middle East & Africa (South Africa, UAE and Saudi Arabia etc.).

With the Stem Cell Therapy market forecast to expand CAGR% in 2020 and with X-X-X-X supposed to be a big beneficiary, it is better positioned than Z-Z-Z-Z for 2020.

According to the AMR market study, Recent trends in consumer preferences market segments such as type, the application will be more challenging. Stem Cell Therapy market segment sales will traverse the $$ mark in 2020.

Unlike classified segments successful in the industry such as by Type (Autologous, Allogeneic) and by End-Users/Application (Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others).

The 2020 version of the Stem Cell Therapy market study is a further split down / narrowed to highlight the latest emerging twist of the industry.

Enquire more before buy at: https://www.amplemarketreports.com/enquiry-before-buy/2020-2029-global-stem-cell-therapy-market-2022421.html

Due to a change in consumer preferences with a review on the latest sales and revenue report submissions, Major vendors in the Global market are trying to get the attention of end-users or consumers by Offerings and additional services.

With using the latest technology and analysis on demand-side, Key players are getting in consumer behavior and their changing preferences.

Again, big investment firms or giants are willing to put more capital to get a key players performance in the market for new applications or products.

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/2020-2029-global-stem-cell-therapy-market-2022421.html

Research Objectives and Purpose

Read More about this report at: https://www.amplemarketreports.com/report/2020-2029-global-stem-cell-therapy-market-2022421.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to deliver reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

https://www.amplemarketreports.com

Read more:
Stem Cell Therapy Market to See Massive Growth by 2026 Osiris Therapeutics, NuVasive - Farming Sector

Read More...

How does the human body react to being in space? – Sciworthy

December 24th, 2020 6:57 am

Since 1961, more than 500 humans have flown into space. However, only 20 astronauts have stayed more than 90 days on long-duration space missions. If humans will one day travel to and from Mars, the round-trip will take 3 years. It is essential then, before those crew members ever launch, that we understand the effects long duration spaceflight has on the human body.

This unique environment consists of extreme conditions such as weightlessness, high radiation, variations in extreme temperature and pressure, among other health stressors. Long duration space flight significantly affects astronaut body mass index and what genes are expressed. Changes in metabolism, vascular health, the gastrointestinal microbiome, and cognitive performance were also observed during spaceflight. These adverse effects resolve upon return to earth as astronauts maintain vigorous exercise and nutrition programs for rehabilitation.

To study in depth the changes taking place in the human body over such a long mission in space, researchers need to look at everything from genetics to body mass. Among the Astronaut corps, NASA had a unique opportunity a set of genetically identical twin astronauts, Scott and Mark Kelly. For 340 days, Scott would be on the International Space Station (ISS), while Mark remained on Earth, both undergoing the same medical analyses, pre-flight, in-flight, and post-flight to catalog the changes between the two.

The results were obtained from samples including saliva, stool, skin, urine and blood. Different molecular level techniques, cognitive tests, and biometric tests were used to understand the genetic, physiological and psychological changes in the astronauts.

The astronauts experienced changes in the expression of over 800 genes during spaceflight. Most of the genes returned to normal after flight, but some did not leading to changes in astronauts genetics and physiology. Space radiation may have damaged their DNA.

The midflight flu vaccination administered by the astronauts worked exactly as it does on Earth. This suggests the primary immune system functions were maintained during the flight, and vaccines were still an effective tool for protection.

Genes related to inflammation were more active, which may result from the human body reacting to long duration space flight. Researchers suggest telomeres (a region of DNA at the end of a chromosome) act as an aging clock in every cell, as we grow older our telomeres grow shorter. Telomere elongation was observed in space, but we cannot conclude that space is a miraculous location that adds to human longevity. Elongation may be due to the exercise and calorie-regulation astronauts maintain inflight.

A rapid shortening of telomeres in less than 45 hours was observed upon astronaut return to Earth, likely due to the extreme stresses associated with landing. Mainly the longer telomeres are associated with healthy lifestyle factors such as good nutrition and regular physical activity. However, it is unknown if telomere lengthening and shortening relate to aging in this case, because of the lack of research conducted on telomeres in microgravity.

Spaceflight might have effects on learning and cognition. The in-space astronaut could complete learning and work tasks with greater speed and accuracy, concluding that spaceflight may affect cognition positively.

Bone density is of great concern for space biology researchers. It is well known that spaceflight causes rapid loss of bone density, decreased muscle mass, and weight loss. These are common physiological changes observed in astronauts due to changes in gene and hormone regulation in space. Furthermore, due to microgravity, blood and fluids move from lower to upper body called headward fluid shift causing an appearance of a puffy face and skinny legs. This fluid shift may lead to increased pressure in the veins and capillaries of the eyes causing vision problems in astronauts.

Research also suggests astronauts are at high risk for dehydration, evidenced by changes in the gene AQP2, which regulates water reabsorption in the body and is a useful indicator of hydration status. On the ISS, the isolated and confined environment of the astronauts puts them in a degree of psychological stress. Meanwhile, eating only freeze-dried or heat-stabilized prepackaged food in space is different from what astronauts are used to eating on Earth. These psychological and nutritional stressors in astronauts negatively affect the function of beneficial gut microbes. This change in the gut microbiome results in alterations of immunity, physiology, and even psychological well-being.

The NASA twin study generated unique biomedical data on the effect of a year-long spaceflight on the human body. Most of the biological changes returned to baseline after the 340-day space mission, suggesting that human health can be mostly sustained over this spaceflight duration. As the researchers suggest, the space environment leads to potential health risks. Exercise, a good diet, and personalized medicine will make multi-year space exploration safe for astronauts. These advancements also have the potential to improve Earth medicine as well.

View original post here:
How does the human body react to being in space? - Sciworthy

Read More...

A century and counting: Ardmore woman turned 100 on Friday – Daily Ardmoreite

December 24th, 2020 6:57 am

Drew Butler| dbutler@gannett.com

In the evening hours of Saturday, December 18, 1920 a little girl was born in Garvin County. On Friday, December 18, 2020 that little girl, Velma Peery, celebrated her 100th birthday at Canoe Brook Ardmore Assisted Living.

Ive still got a lot of life in me, she said. I can do pretty good, but the more I sit around the stiffer I get.

Her son, Lynn Peery shared a few details about his mothers life. She lived in Garvin County for most of her life until moving into an assisted living facility in Ardmore a little over a decade ago. She was married to her husband for 57 years until his death in 1994, and the couple had four sons and one daughter.

Lynn, at the age of 74, is the baby of the family, and he said four of the five siblings are still living. One of his brothers passed away last year after an infection he developed after a surgery.

He credits his mother's and siblings' longevity with honest living and hard work along with the help of genetics.

My grandparents on her side both passed away in their early 80s, Peery said. On my dads side most of them died in their early 50s. My dad had heart surgery at 54 and we were able to keep him for another 20 years until he passed away at the age of 74.

He shared a story about his mother from the day after his father passed.

When my dad passed away, we went up and spent the night, Peery said. The next morning I got up and made coffee for everybody and took her some. She told me that she didnt like that stuff. I said what do you mean you dont like it? You and dad sat and drank coffee every morning for 57 years! She said well, he liked to talk and drink coffee in the morning, and I never liked it but I did it for him. Talk about dedication!

Peery lives in Ardmore as do several of her grandchildren. He said he visits her through the window almost every day and the entire family is looking forward to when they are able to come inside to visit and take her out for day trips.

She said she feels like a tiger in a cage because she cant get out and everybody is stuck inside, he said. We hope to get to where we can get her out to move around a bit. Were also looking forward to getting in and helping her redo her room once all of this is done.

Go here to read the rest:
A century and counting: Ardmore woman turned 100 on Friday - Daily Ardmoreite

Read More...

The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 – PharmiWeb.com

December 24th, 2020 6:57 am

Adrenomyeloneuropathy is a rare genetic neuro-degenerative disease. Adrenomyeloneuropathy is the adult onset of adrenoleukodystrophy caused by the mutation in ABCD1 gene occurs usually in young boys. Adrenomyeloneuropathy disease affect the nerve cells in the spine and brain and the adrenal glands. Adrenomyeloneuropathy symptoms includes stiffness, weakness and pain in the legs. Adrenomyeloneuropathy is also known as progressive spastic paraparesis. Damage to the nerves of the legs which causes unsteadiness and fall, also the bladder, bowel and sexual organs are affected by the adrenomyeloneuropathy. Rare diseases affect vast numbers of people, with current data representing 30 million sufferers in the EU alone and 30 million affected in the US. There is no cure to Adrenomyeloneuropathy. However some treatment might stop the progression of Adrenomyeloneuropathy such as stem cell transplants. Blood testing, MRI test, vision screening and Skin biopsy and fibroblast cell culture are done for the diagnosis for the adrenomyeloneuropathy. Continued advances in the treatment of adrenomyeloneuropathy will further propel the adrenomyeloneuropathy treatment market.

Growing cases of rare disease and development of new and advanced treatment for rare disease is expected to boost the adrenomyeloneuropathy treatment market. Growing preference for healthy lifestyle and favorable government regulation spur the Adrenomyeloneuropathy treatment market in the forecast period. Development of new technology and devices for the diagnosis of genetic disorders will propel the adrenomyeloneuropathy treatment market. Rising focus on the research and development of new therapeutic and drug treatment and growing government funding for the orphan drug is expected to drive the adrenomyeloneuropathy treatment market.

To remain ahead of your competitors, request for a sample here@

https://www.persistencemarketresearch.com/samples/28645

However, stringent regulations for the drug development and high cost of associated with the treatment is expected to hinder the adrenomyeloneuropathy treatment market.

The global adrenomyeloneuropathy treatment market is segmented on basis of disease type, drug type and end user and geography.

Development of novel drugs and undergoing clinical trial for the rare disease is expected to boost adrenomyeloneuropathy treatment market. More than 3,000 drugs are in active development for one of the rare disease. Progress in genomics and biomedical science for the development of rare disease drug is expected to spur the adrenomyeloneuropathy treatment market. Various pharmaceutical companies are focusing on developing drug for the low prevalence disease types and rising funding and collaboration among the key players and government is expected to spur the adrenomyeloneuropathy treatment market.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/28645

The North America market for adrenomyeloneuropathy treatment is expected to retain its dominance, owing to increasing patient pool for rare disease, increasing government funding to accelerate the research and development for rare disease. According to Genetic and Rare Diseases Information Center, more than 25 million Americans are suffering from rare disease in United States.Europe is expected to account for the second largest share in the global adrenomyeloneuropathy treatment market owing to growing clinical trial funding programs for orphan drug development and high prevalence of adrenomyeloneuropathy and high treatment seeking rate. Asia Pacific is expected to show significant growth, owing to increasing diagnosis rate and improvement in healthcare infrastructure. China is expected to show significant growth in the adrenomyeloneuropathy treatment market, due to rising population improving R&D capability, increasing per capita heath spending. Latin America and Middle East & Africa is expected to show growth owing to lack of diagnosis and inadequate healthcare facilities and lack of skilled physicians for Adrenomyeloneuropathy Treatment market.

Examples of some of the key manufacturer present in the global adrenomyeloneuropathy treatment market are Ascend Biopharmaceuticals, Novadip Biosciences, Eureka Therapeutics, Human Longevity, Regeneus, Allogene Therapeutics, BioRestorative Therapies, Immatics Biotechnologies, NewLink Genetics, Cytori Therapeutics, Talaris Therapeutics among others.

You Can Request for TOC Here @

https://www.persistencemarketresearch.com/toc/28645

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsitehttps://www.persistencemarketresearch.com

Source MARKITWIRED

Continued here:
The Adrenomyeloneuropathy Treatment Market to grow on an emphatic note from 2019 to 2029 - PharmiWeb.com

Read More...

Getting to the root of why hair goes gray – messenger-inquirer

December 24th, 2020 6:57 am

Marco Kaltofen was 11 when he noticed his first white hairs. As his hair grew whiter, his middle-school friends started calling him the professor. By his mid-30s, it was completely white, as it had been for three of his grandparents. His parents went white in their 40s, so I had no chance of avoiding this, Kaltofen says.

Now 61, he is a civil engineer who lives in Boston. He wears his white hair in a ponytail. White hair is part of my identity, and I am completely at peace with it, he says.

Then there is Joe Rees, 75, a retired customs attache who lives in Washington. He is balding, but the hair that remains on the sides and in the back is the same dark brown it always has been. He jokingly attributes this to clean living and a pure heart, although, like Kaltofen, it probably is genetic. His mothers black hair didnt start to go gray until she was in her 70s, and was 50/50 when she died at 88, he says.

Still, Id rather be gray than bald, he says. That way, I wouldnt have to worry about wearing a hat all the time.

To be sure, Rees and Kaltofen are exceptions, since most people start graying in their 50s and 60s. Nevertheless, their experiences are among the many mysteries of gray, white or silver-looking hair that scientists are exploring to learn more about aging. They want to know why some people turn gray early and others late or not at all and what this might signal about their health. They also want to understand the factors that hasten graying, and even whether gray hair is reversible which could be a boon to those allergic to hair dye, or who hate spending money to keep the gray away.

Most important, studying gray hair could point to new approaches in promoting healthier aging, says Candace Kerr, health scientist administrator in the National Institute on Agings Division of Aging Biology.

While graying is one of the markers of aging aging is the ultimate risk factor for why hair goes gray it highlights the need for better understanding of the mechanisms that drive aging and age-related diseases, she says. To be able to target these pathways will be critically important for our aging population to live longer and happier lives.

Hair that looks gray, white or silver actually is colorless. Hair color comes from melanin, a pigment produced by cells in the hair follicles. Over time, these cells suffer damage and become depleted, losing their ability to make melanin. This results in new hair without pigment meaning, no color.

People use gray, white and silver interchangeably to describe hair that is turning or has turned. Its appearance whether it looks, gray, white or silver depends on how much natural color, or pigment, remains, experts say. Hair that has lost all its color typically appears white.

Studies have identified a number of factors that also may speed up gray hair, including smoking, diet, stress and genetics.

Our hair color depends on a set of specialized stem cells called melanocyte stem cells, and every time a new hair grows, these melanocyte stem cells have to divide in two and make a new melanocyte, [or] pigment cells, explains Melissa Harris, assistant professor of biology at the University of Alabama at Birmingham. These pigment cells stay in the base of your hair and their job is to produce pigment. These melanocytes reach out skinny arms, called dendritic processes, that shuttle the pigment to the hair shaft as it grows. So if all your melanocyte stem cells disappear, so do your melanocytes and so does your hair pigment. Thus gray hair.

Because stem cells directly influence hair color, studying gray hair can provide insights about why stem cells age and ultimately fail, offering important clues about the workings of other stem cells in the body for example, those found in muscles, bones and organs. In turn, these ultimately could point to whether gray hair could be a marker for disease, or the opposite, a longer life. Previous studies have not shown a relationship between life span and gray hair, including whether late onset of gray hair predicts longevity. Some research, however, indicates that gray or white hair can be a sign of early heart disease, regardless of age.

In some people, gray hair could potentially serve as indication of their health for instance when caused by stress, or a signal for those who may be developing cardiovascular disease, Kerr says. We still need to learn more about whether and, if so, how late onset of gray hair can signal better health and longevity in some people under certain circumstances, as well as whether early graying means stem cells might be aging.

There are many different stem cells in our body which may or may not age by different means, she says. How stem cells mark aging overall and how they could interact to promote aging is an important question.

This is why scientists who study gray hair regard it as a valuable research tool.

As gray hair researchers, we often have to defend why we study a cosmetic characteristic, rather than a life-threatening disease, Harris says. But what is very cool about gray hair from a scientific point of view is that we can see it with our own eyes, meaning we dont have to take invasive biopsies, and it doesnt kill you. We have asked a lot of important and interesting questions about stem cells by studying gray hair in mice. And, we are constantly on the lookout for gray-haired mice so we can use our scientific skills to find out what makes them gray.

A 2018 mouse study by Team Hair-Us (Harris nickname for her lab colleagues) found a connection between MITF (microphthalmia), a transcription factor (a protein involved in gene expression) important in managing pigment production, and the innate immune system, suggesting that some peoples hair may turn gray in response to serious illness or chronic stress. They discovered a relationship between genes involved in hair color and those that trigger an immune response to a viral infection, suggesting this interaction could increase the chances of developing gray hair.

MITF, in a sense, shields melanocyte stem cells from our own immune system, she says. Normally our immune system protects our bodies from infection. But for melanocyte stem cells, too much immune response is bad for their health, and this leads to their loss and to gray hair. Why melanocyte stem cells are so sensitive to our own natural means for protection, we still dont know.

Im very curious to see whether we see an uptick in individuals with gray hair due to coronavirus infection, she says. Unfortunately, we probably wont know because gray hair is rarely documented clinically, unless it is very extreme.

Scientists still dont know why some people turn gray early, late, or not at all, although they suspect genes, nutrients and possibly the immune system play a role in depleting melanocyte stem cells.

There is still much to learn about what regulates these stem cells and what may contribute to their loss, says Ya-Chieh Hsu, associate professor of stem cell and regenerative biology at Harvard University and principal faculty member of the Harvard Stem Cell Institute.

Among other things, Hsu studies the effect of stress on graying. Most of us are familiar with those before-and-after photographs of U.S. presidents most recently Barack Obama showing a striking increase in gray hair during their terms, even in relatively young presidents. Its known as the Marie Antoinette Syndrome, after the 18th-century French queen whose hair allegedly turned white overnight before she went to the guillotine and her death at age 38 during the French Revolution.

With the aging process, we gradually lose melanocyte stem cells one-by-one over a very long period of time, Hsu says. What we found in our research was that the stress can accelerate that process.

Hsu and her colleagues found that stress stimulates the same nerves that trigger the fight-or-flight response, which in turn causes permanent damage to the pigment-producing cells in hair follicles. The fight or flight response is thought to be a good thing in stressful situations because it can drive us and other organisms to respond to danger rapidly, Hsu says. This activation causes a spike in the neurotransmitter norepinephrine. Norepinephrine raises our heartbeat and allows us to react quickly to danger without having to think about it.

But norepinephrine also tells melanocyte stem cells to pump up their activity and proliferate, and too much norepinephrine, in this case triggered by stress, causes the melanocyte stem cells to burst into so much activity it leads to rapid depletion of the stem cell reservoir, she says. If all the stem cells are depleted, no more pigment-producing cells can be produced anymore, and the hair turns gray.

Other stress hormones, ACTH (adrenocorticotropic hormone) for example, can cause melanocyte stem cells to migrate away from the hair follicle before they can produce the melanocytes needed for hair and skin color, according to research. Such hormones are known to increase in the body after stress, and may have the potential to promote the loss of these cells, regardless of age, says study author Mayumi Ito, associate professor in the departments of cell biology and dermatology at the New York University Grossman School of Medicine.

Hsu believes the connection between stress and hair color could reveal additional information about how stress affects other biological processes. How stress affects our tissues is still poorly understood, and one of the powerful aspects about the melanocyte is that it provides a visible and highly trackable system to study stress, she says.

Ito also found that certain cell signaling proteins called endothelins (substances known to constrict blood vessels and raise blood pressure) bind to melanocyte stem cells and, in doing so, keep them healthy. Interrupting the process causes cell loss and early graying in mice. They are studying whether the same happens in human hair follicles, hoping to find ways to preserve or regenerate the key stem cells that give hair its color.

All of this raises the intriguing possibility that scientists could discover ways to prevent or reverse gray hair.

Team Hair-Us recently published a paper describing a topical drug combination that increased melanocyte stem cells in gray mice, ridding them of their gray and restoring their original fur color perhaps for good. Because the treatment originally developed to regrow hair replenished pigment-producing stem cells, the effects could be long-lasting, Harris says.

We didnt keep the mice forever so we dont know, says Harris, who plans more studies. This has made us very interested in whether gray hair really is permanent, and if we can do something about it. We really want to know and so does everyone else we talk to is whether and when we can bring this to humans.

See the original post:
Getting to the root of why hair goes gray - messenger-inquirer

Read More...

5 Ways to Maintain Good Vision and Healthy Eyes – Health Essentials from Cleveland Clinic

December 24th, 2020 6:55 am

Your eyes play a crucial role in how you move through the world and enjoy your life, from the moment you wake up to the moment you go to sleep.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services.Policy

They do the important job of capturing light. Then, different parts of the eye system (or ocular system) work together, connecting with neurons that translate and deliver messages to the brain as visual images.

For this reason, its important to keep your eyes healthy. Follow these simple measures to maintain good vision and enjoy lifelong eye health.

Eye specialists are trained to determine and improve your vision with eyeglasses, contact lenses and eye exercises. They can provide total eye care, from examinations and vision correction to the diagnosis and treatment of eye disease, says ophthalmologist Michael Millstein, MD.

You should visit your optometrist or ophthalmologist for an eye exam once every year, or if you experience eye infections or symptoms of disease such:

Eye disease is the No. 1 cause of blindness. Most diseases that cause blindness, likeglaucomaanddiabetes, can be treated or slowed down if theyre diagnosed and managed properly, Dr. Millstein says.

While theres no cure for some eye disorders, there have been major medical advances for age-relatedmacular degeneration andcataracts. By getting regular exams and discussing your family history, you and your doctor will be better able to anticipate, prevent and treat eye disease.

Not wearing your prescribed eyeglasses or contacts wont cause disease, but it can create discomfort from eyestrain,headaches or possibly even injury brought on by the lack of safe vision.

If you find wearing prescriptive lenses to be uncomfortable, ask your doctor about alternatives, like switching from eyeglasses to contact lenses or exploring corrective surgery.

Ultraviolet (UV) radiation comes from sunlight, tanning beds, black-light lamps and some other forms of light. If youre frequently exposed to UV rays, this can lead to an increased risk of cataracts or yellow raised spots on the surface of the white of the eye, such as pingueculas and pterygiums. Eye diseases such as macular degeneration, solar retinitis and corneal dystrophies have all been linked to UV exposure.

Your eyes may be more sensitive if theyre a light color, or if youre taking specific medications. You can protect your eyes while youre out in the sun by wearing prescription sunglasses, clip-on sunglasses or UV-blocking contact lenses.

Wearing safety glasses and protective goggles when you play sports or work with hazardous materials lowers your risk for eye injury, vision damage and complete loss of sight.

Being actively involved in your eye health and working with your optometrist and ophthalmologist increases your chances for maintaining good eye health and eyesight throughout your life, Dr. Millstein says.

See the original post:
5 Ways to Maintain Good Vision and Healthy Eyes - Health Essentials from Cleveland Clinic

Read More...

COVID-19 may trigger endophthalmitis, a rare eye infection that causes vision loss – TheHealthSite

December 24th, 2020 6:55 am

The COVID-19 virus has the chilling ability to invade different body organs and cause serious damage that can last for years. It can damage your body organs, affect your skin and even cause neurological problems. The damage it causes to your lungs can be permanent. This virus can also affect your eyes and give you conjunctivitis and sore eyes. Now, it has come to light that the novel coronavirus may trigger inflammation of the eyes that can lead to vision loss. Three COVID-19 patients in the US developed keratitis, an inflammation of the cornea. This is serious because this condition can lead to a sight-threatening infection of the tissues or fluids inside the eyeball called endophthalmitis. Also Read - COVID-19 vaccine: Aurobindo Pharma Inks Pact With Covaxx to develop a vaccine for India

According to a new study at the Zucker School of Medicine at Hofstra University in Hempstead, New York, this is a rare development, but it can happen. Having three cases of endophthalmitis in such a short time is exceedingly rare, and because they were all tied to COVID-19 infection it needed to be investigated, say researchers. They added that the whole point is to alert people of the association, though they cannot say specifically that COVID causes it. However, it cannot be ruled out. Also Read - Can COVID-19 vaccines bring the pandemic under control?

Of the three patients, one died from COVID-19, another had to have an eye removed despite heroic efforts to save the eye, and a third lost all sight, said researchers. All the patients were in their 60s and were treated at Northwell Healths Ophthalmology Department. Also, the three patients had underlying health problems that may have made their COVID-19 worse and made them more susceptible to other associated health conditions. The only other eye condition linked to COVID-19 has been conjunctivitis, also called pink eye, which is a minor infection. Also Read - Has new strain of Covid-19 virus already entered India? This is what health ministry says

Endophthalmitis is very rare, but it can be caused by a virus. According to one of the researchers, other cases of endophthalmitis linked to COVID-19 patients have also been reported. One of them is in Boston and another in Australia. Usual symptoms of endophthalmitis includes pain, redness and discharge from the eye. You must also be alert to swelling of the eyelids and you may experience reduced vision. If you notice any of these symptoms, consult a doctor immediately. Early treatment of this associated complication can save your vision.

According to researchers, it is unusual for keratitis to progress to endophthalmitis. A 2012 study says that only 27 of around 10,000 eyes over 15 years developed endophthalmitis because keratitis. One expert thinks that because keratitis progressing to endophthalmitis is so rare, its not possible from these findings to say that the connection between these conditions is anything but coincidental. According to them, while it is possible that the keratitis was related to COVID-19, there are very few reports to suggest this is at all common. They agree that further research is needed to confirm the findings.

(With inputs from Agencies)

Published : December 22, 2020 6:36 pm

Link:
COVID-19 may trigger endophthalmitis, a rare eye infection that causes vision loss - TheHealthSite

Read More...

Vision Benefits of America Grants $500,000 to the Pennsylvania Vision Foundation – PRNewswire

December 24th, 2020 6:55 am

PITTSBURGH, Dec. 23, 2020 /PRNewswire/ --Vision Benefits of America, Inc. (VBA), a commercial group benefits organization, today announced donations totaling $500,000 to the Pennsylvania Vision Foundation in 2020. The donations will support the foundation's mission to preserve human eyesight.

"VBA is committed to the Pennsylvania Vision Foundation and those in need of high-quality eye care," said Jeff Hollowood, CEO and President at VBA. "We are proud to increase our annual contribution to the foundation and support our Pittsburgh neighbors."

By partnering with many local, community-based non-profit organizations, the Foundation's primary Vision Benefit Program provided routine vision exams, prescription lenses and frames to approximately 685 uninsured Pennsylvanians this year. In 2020, the Foundation also granted a total of $52,000 to a host of non-profit agencies that partner and support programs serving its mission.

"The foundation is deeply appreciative of VBA's generous contribution," said Andrew Leitzel, O.D., Executive Director. "As a non-profit organization, these funds are critical to advancing our impact across the state. VBA truly supports our community and exemplifies neighbors helping neighbors."

VBA made charitable donations to organizations including Allegheny Cleanways, Andrew Carnegie Free Library and Music Hall, Big Brothers Big Sisters of Greater Pittsburgh, Boys and Girls Club of Carnegie, Carnegie Police Department Toys for Tots, Carnegie Salvation Army Food Pantry, Community Kitchen Pittsburgh, Jeremiah's Place, Mt. Nittany Health Foundation, Outreach Teen and Family Services, Reading Ready Pittsburgh, Sarah Heinz House Association, Storehouse for Teachers and 412 Food Rescue.

VBA has been a proud partner of the foundation since its inception in 2007.

About VBAFounded in 1965 as one of the first preferred provider organizations (PPO) in the nation, VBA has proudly offered group vision benefits to corporations, municipalities, schools, health and welfare funds, hospitals and health maintenance organizations for over 50 years. Seeking to capitalize on its experience and expand its offerings beyond vision, VBA also provides cost-effective dental solutions across the nation through plans administered and underwritten by the TruAssure Insurance Company. Some plans may not be available in all states. For information, please visit http://www.vbaplans.com.

About the Pennsylvania Vision Foundation

The Pennsylvania Vision Foundation, an affiliate of VBA, was founded in 2007 as a 501(c)(3) charitable foundation. Its mission is to provide essential eye care through vision exams, prescription lenses and frames to those in need. Its purpose is to conduct and finance projects that will help foster and preserve human eyesight through the science of optometry. It strives to help support advancement in optometry through education and technology. To date, the Foundation has proudly assisted more than 6,055 uninsured Pennsylvanians.

Media Contact

Contact: Emily ShraderTelephone: 412-881-4900 x 232Email: [emailprotected]

Related Images

vision-benefits-of-america-grants.png Vision Benefits of America Grants $500,000 to Pennsylvania Vision Foundation

SOURCE VBA

See the original post:
Vision Benefits of America Grants $500,000 to the Pennsylvania Vision Foundation - PRNewswire

Read More...

Such a Personal, Private Thing: Rethinking the Home Pregnancy Test – The New York Times

December 24th, 2020 6:55 am

When Tiffany Jesteadt, who was born blind because of a hereditary disorder, thought she might be pregnant, her husband, who is sighted, read her the results, not by choice but by necessity. It took away some of the magic, she said, explaining how shows and movies often depict wives surprising their husbands by cleverly hiding the positive pregnancy test.

Getting to tell your husband it is cultural, said Ms. Jesteadt, 33, an organization development practitioner for the U.S. Marine Corps. While she and her husband tell each other everything, she said, disclosing information about her own body is something that a woman should be able to control.

Making the test experience more private also helps reduce the judgment many blind women say they experience on their paths to motherhood.

Josselyn Sosa was a college senior when she found out she was pregnant. At first, Ms. Sosa turned to a trusted friend who accompanied her to buy a test in a CVS store that she then took in its bathroom. Her friend also had impaired vision and couldnt read the results, either. So Ms. Sosa visited the health center at her small college in Texas, where a doctor told her, I am so sorry, but it came back positive.

She felt she could provide her opinion, said Ms. Sosa, 28, who was born with congenital glaucoma in her right eye and lost sight in her left eye because of retinal detachment when she was 12. She had been dating her now-husband, who is also blind, for only a short time. I just wanted to get out to deal with it by myself, she said. It was such a big deal for me.

Ms. Sosa went on to deliver a baby girl, now 4 years old. She graduated this month with a degree in hospitality administration and shes pregnant with her second child, due in June.

For her current pregnancy, Ms. Sosa used the Be My Eyes app. It was a better experience, but she still felt she was giving up her privacy, she said.

See the original post:
Such a Personal, Private Thing: Rethinking the Home Pregnancy Test - The New York Times

Read More...

Did a cataract operation improve my memory? – The Irish Times

December 24th, 2020 6:55 am

The Irish playwright Thomas Kilroy said that when he had cataracts removed from his eyes his memory improved. He was delighted with the improvement in his eyesight and the memory boost was a welcome bonus. Bad eyesight and memory loss had been bothering him for some time. Now, life was taking on a welcome new outlook.

I was amazed at this claim. Yes, of course his eyesight improved when the cataracts were removed, but surely memory is a completely different thing altogether? Was he serious? I must admit, I was highly sceptical. It didnt seem possible to my non-medical/scientific brain that such a thing could happen. How could his memory improve? I mean, we all know playwrights have wonderful imaginations. After all, that is one of the reasons why they write plays in the first place, isnt it?

The reason I was so interested in this subject was because I was going for a cataract operation the following week and, as it so happened, my memory was beginning to slip (why wouldnt it at 80 years?). So, if this guy is right, I could be killing two birds with the one stone. Bingo, new eyes and my once great memory back on track. I might be able to get my job back in the newsroom, although I might appear a bit of a dinosaur to the present bright young incumbents.

By the way, for those of you who do not know what cataracts are, they are a clouding of the lens in the eye which leads to a decrease in vision. Cataracts cause half of all cases of blindness and 33 per cent of visual impairment worldwide. They are most commonly due to aging.

They kind of sneaked up on me. Never realised what was happening. I knew my driving was going to hell and my judgment was not as good as it used to be. My reversing into parking spaces was poor. Driving was particularly dodgy at night and headlights from other cars would blind me. I could only drive slowly, which usually resulted in younger, impatient drivers tailgating me and trying to run me off the road. I nearly gave up driving at night, except to drop down to the village for an evening meal with my wife.

Being a slow learner, I didnt realise what was going on. I put it down to old age. I have convinced myself that everything that goes wrong nowadays is due to old age. The cracks are starting to appear, big time. Here was the big clue in front of me hopeless, dangerous night driving and I could not see the reason for it. (Ill never get into the Garda Sochnas detective unit, thats for sure.)

The clues were everywhere. But, like Mr Magoo, I could not see them. Take my golf for instance. I mean I was never in the Rory McIlroy league or ever likely to be, but I could always finish 18 holes without having a heart attack or losing too many balls into the water or the gorse bushes. But suddenly I began misjudging shots, hitting fresh-air shots, handicap going out, losing bets on rounds with friends. Yes, the roof was falling in. And still the penny never dropped. Never copped on that all this was very strange. No, it was simply old age stalking me again: the usual mantra.

Then, suddenly, the sorry saga came to an end and the reason for my discomfort and frustration was explained to me.

I had gone to my optician to get a new pair of reading glasses. She did an eye test and announced I had bad cataracts in one eye and they were starting to develop in the second. They would have to be removed immediately.

Wow, a mixture of relief and concern followed this diagnosis. Glad that I knew what had been happening to me, but a little concerned about what would happen in the operation (would it go wrong and would I bleed to death?)

I need not have worried. It was the easiest and most painless hospital procedure I ever had. It only took about half an hour. It is a simple operation with an almost 100 per cent success rate. I had spent more time answering questions and filling in forms in triplicate then having the actual job done.

After the operation I was wheeled back to my ward and got a lovely cup of tea and one of the nicest scones I ever tasted. Id nearly go back again to get one of those scones.

I can now proudly declare that my eyesight is exceptionally good. I can practically see the grass growing. No problem with night driving. Long distance eyesight is simply brilliant. My long distance sight is so good that my golf colleagues are constantly asking me to tell them where their ball went. I am quite chuffed by this new recognition. I am pleased to be able to help. Of course I have no difficulty in finding my own ball, mainly because it doesnt go very far.

Has the operation improved my memory, as it did for Thomas Kilroy? I suppose it has to a certain extent insofar as everything has quickened up considerably and all my mental reactions seem to be better. Im generally much sharper in my mental reflexes. Sorry for doubting you, Thomas. But please dont ask me to remember names. It was a big problem before the operation and it still is, Im afraid.

That reminds me of the old memory joke about the man who visits his friend in a nursing home. To test the patient he posed the question: Do you know who I am? The friend replies: Ask the matron, shell tell you.

Read more:
Did a cataract operation improve my memory? - The Irish Times

Read More...

Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Spero Therapeutics Inc (SPRO) is near the top in its industry group according to InvestorsObserver. SPRO gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Spero Therapeutics Inc gets a 88 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spero Therapeutics Inc (SPRO) stock has gained 17.83% while the S&P 500 is down -0.12% as of 10:24 AM on Tuesday, Dec 22. SPRO is up $3.39 from the previous closing price of $19.00 on volume of 235,658 shares. Over the past year the S&P 500 has risen 14.47% while SPRO is up 114.46%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

Read the rest here:
Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Aclaris Therapeutics Inc (ACRS) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

A rating of 78 puts Aclaris Therapeutics Inc (ACRS) near the top of the Biotechnology industry according to InvestorsObserver. Aclaris Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Aclaris Therapeutics Inc also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 29 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aclaris Therapeutics Inc (ACRS) stock has gained 9.93% while the S&P 500 has fallen -0.12% as of 10:24 AM on Tuesday, Dec 22. ACRS has risen $0.60 from the previous closing price of $6.04 on volume of 654,019 shares. Over the past year the S&P 500 is up 14.47% while ACRS has risen 264.84%. ACRS lost -$1.35 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aclaris Therapeutics Inc (ACRS) Stock.

Continued here:
Is Aclaris Therapeutics Inc (ACRS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 66 rating InvestorsObserver gives to Allakos Inc (ALLK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ALLKs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Allakos Inc (ALLK) stock has risen 0.58% while the S&P 500 has fallen -0.22% as of 3:25 PM on Tuesday, Dec 22. ALLK is higher by $0.84 from the previous closing price of $144.00 on volume of 295,894 shares. Over the past year the S&P 500 is up 14.35% while ALLK is higher by 41.36%. ALLK lost -$2.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allakos Inc (ALLK) Stock.

Continue reading here:
Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Frequency Therapeutics Inc (FREQ) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Frequency Therapeutics Inc (FREQ) is near the top in its industry group according to InvestorsObserver. FREQ gets an overall rating of 74. That means it scores higher than 74 percent of stocks. Frequency Therapeutics Inc gets a 90 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 74 means the stock is more attractive than 74 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Frequency Therapeutics Inc (FREQ) stock is higher by 6.57% while the S&P 500 is lower by -0.11% as of 10:57 AM on Tuesday, Dec 22. FREQ has risen $2.08 from the previous closing price of $31.66 on volume of 140,241 shares. Over the past year the S&P 500 is higher by 14.48% while FREQ has risen 87.13%. FREQ lost -$0.69 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Frequency Therapeutics Inc (FREQ) Stock.

Read the original here:
Is Frequency Therapeutics Inc (FREQ) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Is Crispr Therapeutics AG (CRSP) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

Crispr Therapeutics AG (CRSP) is around the top of the Biotechnology industry according to InvestorsObserver. CRSP received an overall rating of 65, which means that it scores higher than 65 percent of all stocks. Crispr Therapeutics AG also achieved a score of 80 in the Biotechnology industry, putting it above 80 percent of Biotechnology stocks. Biotechnology is ranked 33 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Crispr Therapeutics AG (CRSP) stock has risen 17.22% while the S&P 500 is down -0.3% as of 2:36 PM on Monday, Dec 21. CRSP has gained $25.59 from the previous closing price of $148.61 on volume of 4,067,713 shares. Over the past year the S&P 500 has risen 14.71% while CRSP has gained 156.63%. CRSP lost -$3.25 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Read more:
Is Crispr Therapeutics AG (CRSP) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Spectrum Pharmaceuticals, Inc. (SPPI) the Top Pick in the Biotechnology Industry? – InvestorsObserver

December 22nd, 2020 4:59 pm

The 45 rating InvestorsObserver gives to Spectrum Pharmaceuticals, Inc. (SPPI) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 49 percent of stocks in the Biotechnology industry, SPPIs 45 overall rating means the stock scores better than 45 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 45 would rank higher than 45 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Spectrum Pharmaceuticals, Inc. (SPPI) stock is trading at $4.27 as of 11:42 AM on Monday, Dec 21, a drop of -$0.10, or -2.29% from the previous closing price of $4.37. The stock has traded between $4.22 and $4.50 so far today. Volume today is light. So far 821,900 shares have traded compared to average volume of 1,733,705 shares.

Click Here to get the full Stock Score Report on Spectrum Pharmaceuticals, Inc. (SPPI) Stock.

Link:
Is Spectrum Pharmaceuticals, Inc. (SPPI) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index – GlobeNewswire

December 22nd, 2020 4:59 pm

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. According to NASDAQ, the NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume. The index currently has 198 securities as its components. For more information about the NBI, please visit https://indexes.nasdaqomx.com/index/overview/nbi.

About Arcutis - Bioscience, applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit http://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

Continued here:
Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index - GlobeNewswire

Read More...

Page 258«..1020..257258259260..270280..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick